Dade Behring, Inc. and Roche Diagnostics Grant HIV-1 Group O Rights to DiaSorin S.p.A.

Published: Jul 16, 2007

DEERFIELD, Ill.--(BUSINESS WIRE)--Dade Behring Inc. (NASDAQ:DADE) and Roche Diagnostics announced today that they have granted DiaSorin certain rights related to the development, marketing and manufacturing of immunoassays that can be used for the detection of HIV(human immunodeficiency virus)-1 group O. HIV tests are used to screen patients and also blood donations for HIV infections. By adding the capability of detecting HIV-1 group O to HIV tests, a laboratory can offer more sensitive testing that diagnoses a wider range of HIV infections, therefore reducing the likelihood for a patient to be misdiagnosed or a blood donation to be inaccurately screened for HIV.

Back to news